Researchers at the Icahn School of Medicine and collaborators reported IL‑12‑producing CAR T cells that target tumor‑associated macrophages (TAMs) and remodel the immunosuppressive tumor microenvironment. Preclinical data in metastatic ovarian and lung cancer models showed improved survival and tumor control by disarming TAMs, enabling endogenous anti‑tumor immunity. The work, published in Cancer Cell, positions myeloid‑directed CAR T as a strategy to overcome barriers to solid tumor immunotherapy.